Next Generation Sequencing Services
ResearchDx has CLIA validated multiple NGS assays for analysis of ctDNA in plasma (liquid biopsy) including oncology focused panels. These include the 3 Avenio panels from Roche and the TSO panel from Illumina:
The Targeted Panel: This allows for the analysis of 17 oncology related genes, including those published in the National Comprehensive Cancer Network (NCCN) guidelines.
The Expanded Panel: The expanded panel includes the 17 NCCN guideline related genes as well as 60 additional biomarkers that are currently being analyzed in oncology clinical trials to determine their utility
The Surveillance Panel: True to its name the surveillance panel has been optimized with the guideline genes as well as 180 additional genes to allow for longitudinal analysis that monitors tumor burden (TMB) and minimal residual disease (MRD).
The TruSight Oncology (TSO) 500 panel: The TSO panel is designed for the SNV, Indel, CNV and fusion analysis of 523 oncology related genes making it a great biomarker discovery tool. It also analyzes Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI).
CUSTOM panel development
ResearchDx will develop and validate your NGS assay and using the same rigor and attention to detail as our currently validated panels
Equivalency studies and orthogonal methodology
We can support your validation studies with equivalency work or using one of our NGS panels as an orthogonal method.
Schedule a consultation to discuss your Next Generation Sequencing Service needs.
Our CAP/CLIA certified lab, PacificDx offers state-of-the-art facilities and expertise to meet your immediate clinical and pre-clinical needs for high-quality clinical and biopharmaceutical testing services.